Chlamydial infection, caused by Chlamydia trachomatis, is the most
common contagious sexually transmitted infection and results in
significant economic cost and morbidity worldwide. Occurs most
commonly in young sexually active population, C. trachomatis causes
urethritis in men and cervicitis in women, as well as extra-genital
infections, including pharyngeal and rectal infections. Asymptomatic
infections are common in both men and women. Untreated chlamydial
infection may cause severe abnormalities related with the upper
reproductive tract, mainly in younger women, including salpingitis,
infertility, and ectopic pregnancy. Maternal infection is associated
with serious adverse results in neonates, such as low birth weight,
preterm birth, nasopharyngeal infection, chlamydial conjunctivitis,
and pneumonia. C. trachomatis can be diagnosed by culture, Nucleic
Acid Amplification Tests (NAATs), Direct Fluorescent Tests, and
others (ELISAs).
Report Overview @
https://www.transparencymarketresearch.com/chlamydia-infection-diagnostic-therapeutic-market.html
This report on the global chlamydia infection diagnostics and
therapeutics market analyzes the current and future prospects of the
market. The markets of diagnostics and therapeutics are independently
analyzed as two separate markets within the report. The market for
chlamydia infection therapeutics is segmented based on product type,
end-user and region, while the market for chlamydia infection
diagnostics is segmented on the basis of diagnostics and end-user.
The report comprises an elaborate executive summary, including a
market snapshot that provides overall information of various segments
and sub-segments. The research is a combination of primary and
secondary research. A detailed qualitative analysis of factors
responsible for driving and restraining market growth and
opportunities has been provided in the market overview section.
Market revenue in terms of US$ Mn for the period between 2015 and
2025 along with the compound annual growth rate (CAGR %) from 2017 to
2025 are provided for all the segments, considering 2016 as the base
year. Market related factors such as global incidence/prevalence of
sexual transmitted infection, global incidence/prevalence of eye
infection, cost of sexual transmitted infection in U.S (2010-2015),
and historical year-on-year growth have been taken into consideration
while estimating the market size. Growth rates for each segment
within the global chlamydia infection diagnostics and therapeutics
market have been determined after a thorough analysis of past trends,
demographics, future trends, technological developments, clinical
trials, and regulatory requirements. These factors would help the
market players to take strategic decisions in order to strengthen
their positions and expand their share in the global market.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8212
Based on product type, the global chlamydia infection diagnostics and
therapeutics market has been segmented into diagnostics and
therapeutics. Chlamydia infection diagnostics segment further
segmented into nucleic acid amplification tests (NAATs), direct
fluorescent tests, and others (ELISAs).
The therapeutics used for treatment of chlamydia infection include
Macrolides, Quinolones, Sulfonamides, Tetracycline, and
Aminopenicillins. Macrolides are the antibiotics most commonly
prescribed to treat chlamydia infection.
Geographically, the global chlamydia infection diagnostics and
therapeutics market has been segmented into five regions: North
America, Europe, Asia Pacific, Latin America, and Middle East &
Africa. In addition, the regions have been further segmented by major
countries for the chlamydia infection therapeutics market. These
include the U.S., Canada, Germany, France, Spain, Italy, U.K.,
Russia, China, Japan, India, Brazil, Mexico, GCC countries, and South
Africa. The competition matrix section included in the report is
likely to assist the existing players to increase their market shares
and new companies to establish their presence in the global chlamydia
infection diagnostics and therapeutics market. The report also
profiles major players in the chlamydia infection diagnostics and
therapeutics market based on various attributes such as company
overview, financial overview, SWOT analysis, key business strategies,
product portfolio, and recent developments. Key companies profiled in
the report include Bio Rad laboratories, Novartis AG, F Hoffmann-La
Roche, Abbott Laboratories, Danaher, bioMerieux, DiaSorin SpA,
Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and
Company.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=8212
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
